Treg cell therapy for COVID-19 and acute respiratory distress
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new cell therapy using Treg cells from thymic tissue to calm an overactive immune response in severe COVID-19 and ARDS. It aims to improve breathing and reduce inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have severe lung injury from COVID-19 or other causes with bilateral lung infiltrates and low oxygen levels
- Have high inflammation markers like IL-6, ferritin, or C-reactive protein
- Not be pregnant or breastfeeding
- Have a body mass index (BMI) of 35 or less
- Not have serious bleeding issues (low platelets) or low white blood cell count
- Be free of active hepatitis B, C, or HIV infections
- Not have other major health problems like autoimmune disease, cancer, or prior organ transplant
- Not have used certain immune-suppressing drugs or other cell therapies recently
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a cell treatment (Treg cells made from a child’s thymus tissue) to help prevent the body from rejecting a new heart. It may help reduce rejection risk, but it is experimental and involves added risks and follow-up.
This trial tests whether using a blood test to measure inflammation (IL-6) can help doctors decide if you should get either dexamethasone or tocilizumab for COVID-19 or other acute breathing problems. The goal is to find the best treatment faster and reduce side effects.
This trial tests whether an injection of stem cells from umbilical cords can help people with severe ARDS (a type of lung failure) recover faster. It is for those who have not improved after standard treatment and whose ARDS is caused by an infection (not COVID-19).
This trial tests donated (allogeneic) fat-derived stem cells to see if they improve outcomes in adults with severe or critical COVID-19. It may help calm severe lung/immune problems, but whether it works and is safe will be studied in this Phase 2 study.
This study tests an experimental cell therapy (GKL-006RTU) for people with moderate to severe ARDS caused by an infection. If you qualify, you may receive this treatment alongside standard care.
This early-phase study tests immune cells from a matched family donor (made to target the COVID-19 virus) to see if they can help people with mild-to-moderate COVID-19 who are hospitalized and at higher risk for getting sicker. It aims to check safety first and also look for signs of benefit.
Hear when a new Systemic Inflammatory Response Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.